Opthea Unveils Sozinibercept’s Promise to Revolutionize Wet AMD Treatment

• Sozinibercept targets VEGF-C/D pathways, complementing existing anti-VEGF-A therapies
• Phase 3 trials COAST and ShORe enrolled nearly 2,000 patients globally with topline data expected mid-2025
• Potential FDA Biologics License Application (BLA) submission in first half of 2026 with fast track and priority review prospects
• U.S. wet AMD market valued at approximately $7 billion with over 1.2 million treated eyes annually